Skip to main content

New Leaf Venture Partners, L.L.C.

13F filer · CIK 0001631614
Last filed Nov 14, 2025
Inactive · not filing 13F
13F portfolio value$43MU.S. long equity reported on 13F
Positions70 new · 1 closed
Net flow last quarter-$644KBuys minus sells
Top 10 positions weight100.0%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q3 2025Reported Nov 14, 20257 positions
EWTXEdgewise Therapeutics, Inc.$16.7M38.82%0.97%Not reportedQ1 2021
ARVNArvinas, Inc.$13.5M31.38%2.24%Not reportedQ3 2018
CRNXCrinetics Pharmaceuticals, Inc.$5.87M13.64%0.15%Not reportedQ3 2018
COGTCogent Biosciences, Inc.$3.6M8.37%0.18%Not reportedQ4 2020
RLYBRallybio Corp$1.65M3.83%7.87%Not reportedQ3 2021
ALECAlector, Inc.$1.01M2.33%0.32%Not reportedQ1 2019
PASGPassage BIO, Inc.$702K1.63%2.75%-30.0%Q1 2020
Q2 2025Reported Aug 13, 20258 positions
PASGPassage BIO, Inc.$20M37.74%78.58%Not reportedQ1 2020
EWTXEdgewise Therapeutics, Inc.$13.5M25.51%0.98%Not reportedQ1 2021
ARVNArvinas, Inc.$11.7M22.04%2.17%Not reportedQ3 2018
CRNXCrinetics Pharmaceuticals, Inc.$4.06M7.66%0.15%Not reportedQ3 2018
COGTCogent Biosciences, Inc.$1.8M3.40%0.22%Not reportedQ4 2020
RLYBRallybio Corp$1.12M2.11%7.92%Not reportedQ3 2021
ALECAlector, Inc.$475K0.90%0.34%Not reportedQ1 2019
ITRMIterum Therapeutics plc$343K0.65%0.86%Not reportedQ2 2018
Q1 2025Reported May 13, 20259 positions
EWTXEdgewise Therapeutics, Inc.$22.7M50.47%1.08%Not reportedQ1 2021
ARVNArvinas, Inc.$11.1M24.79%2.17%Not reportedQ3 2018
CRNXCrinetics Pharmaceuticals, Inc.$4.73M10.53%0.15%Not reportedQ3 2018
RLYBRallybio Corp$2.15M4.78%7.93%Not reportedQ3 2021
COGTCogent Biosciences, Inc.$1.5M3.35%0.22%Not reportedQ4 2020
RCKTRocket Pharmaceuticals, Inc.$1.01M2.24%0.14%Not reportedQ4 2022
PASGPassage BIO, Inc.$882K1.96%4.02%Not reportedQ1 2020
ITRMIterum Therapeutics plc$424K0.95%1.00%Not reportedQ2 2018
ALECAlector, Inc.$418K0.93%0.34%Not reportedQ1 2019
Q4 2024Reported Feb 13, 20259 positions
ARVNArvinas, Inc.$30.4M40.64%2.30%+10.5%Q3 2018
EWTXEdgewise Therapeutics, Inc.$27.5M36.77%1.09%-33.7%Q1 2021
CRNXCrinetics Pharmaceuticals, Inc.$7.21M9.64%0.15%Not reportedQ3 2018
RLYBRallybio Corp$3.17M4.24%63.63%Not reportedQ3 2021
COGTCogent Biosciences, Inc.$1.96M2.61%0.23%Not reportedQ4 2020
RCKTRocket Pharmaceuticals, Inc.$1.89M2.53%0.14%Not reportedQ4 2022
PASGPassage BIO, Inc.$1.42M1.89%79.01%Not reportedQ1 2020
ALECAlector, Inc.$642K0.86%0.34%Not reportedQ1 2019
ITRMIterum Therapeutics plc$611K0.82%1.25%Not reportedQ2 2018
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.